Pneumococcal disease and conjugate vaccines

Càmara, Jordi; Ardanuy, Carmen

doi:10.1016/j.eimc.2018.07.012

Cited by 2 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The capsular polysaccharide is the main pneumococcal virulence factor, and its diversity, more than 95 serotypes, is the basis of the current vaccine (and of those in development). The introduction of the heptavalent pneumococcal conjugate vaccine (PCV7) for children in the early 2000s and thereafter PCV10 and PCV13 was associated with a decline in IPD caused by PCV serotypes in children and adults (herd protection) [1e5, 9,10]. Besides PCVs, a 23valent pneumococcal polysaccharide vaccine (PPV23), not effective against IPD in children under 2 years old, is also available.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Emerging non-13-valent pneumococcal conjugate vaccine (PCV13) serotypes causing adult invasive pneumococcal disease in the late-PCV13 period in Spain

González-Díaz

Càmara

Ercibengoa

et al. 2020

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Objective: An early reduction of adult invasive pneumococcal disease (IPD) was observed after the 13valent pneumococcal conjugate vaccine (PCV13) introduction for children in Spain. We analysed the epidemiology of adult IPD in the late-PCV13 period. Methods: This was a prospective multicentre study of adult IPD involving six hospitals. Strains were serotyped, genotyped and studied for antimicrobial susceptibility. The late-PCV13 period was compared with the pre-and early-PCV13 periods. Results: A total of 2197 episodes were collectedd949 in 2008e2009, 609 in 2012e2013 and 639 in 2015 e2016. The initial decrease of IPD observed (from 12.3/100 000 to 8.1/100 000; 2008e2009 versus 2012 e2013) plateaued in 2015e2016 (8.3/100 000). IPD due to PCV13 serotypes decreased (from 7.7 to 3.5 to 2.3/100 000; p < 0.05), whereas IPD caused by non-PCV13 serotypes increased (from 4.5 to 4.6 to 6.0/ 100 000; p < 0.05). The most frequent serotypes in the late-PCV13 period were: 8 (15.1%), 3 (10.5%), 12F (7.9%) and 9N (5.4%). These serotypes were related to major genotypes: CC53 (59.8%) and CC404 (30.4%) for serotype 8, CC180 (64.1%) and CC260 (28.1%) for serotype 3, CC989 (91.7%) for serotype 12F and CC67 (84.8%) for serotype 9N. Penicillin-non-susceptibility (21.2%) was associated with serotypes 11A (CC156), 14 (CC156) and 19A (CC320), and macrolide-resistance was related to serotypes 24F and 19A. Rates of pneumococcal meningitis remained stable throughout the periods (ranges 0.9, 0.8 and 1.0/100 000). Conclusions: The initial decrease of adult IPD observed after PCV13 introduction for children has been balanced by the rise of non-PCV13 serotypes. The spread of antibiotic-resistant lineages related to non-PCV13 serotypes (11A and 24F) could be a threat for the treatment of serious pneumococcal diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Furthermore, we have analysed the serotype distribution and the clonal composition of the major emerging non-PCV13 serotypes. During the study period, PCV13 was approved for adult vaccination, however it was not included in the official adult vaccination schedule in Spain [9].…”

Section: Introductionmentioning

confidence: 99%

Emerging non-13-valent pneumococcal conjugate vaccine (PCV13) serotypes causing adult invasive pneumococcal disease in the late-PCV13 period in Spain

González-Díaz

Càmara

Ercibengoa

et al. 2020

Clinical Microbiology and Infection

View full text Add to dashboard Cite

show abstract

“…Pneumococcal conjugated vaccines (PCV) include the serotypes more commonly found among IPD. In Spain, three conjugate vaccines had been licensed: the first one in 2001, PCV7, targeted serotypes 4, 6B, 9V, 14, 18C, 19F and 23F; the second in 2009, PCV10, added serotypes 1, 5 and 7F and PCV13 in 2010 added serotypes 3, 6A and 19A [3]. The natural ability of S. pneumoniae to undergo genetic transformation allows pneumococci to change the capsule (capsular switching) which allows them to escape vaccine pressure.…”

Section: Introductionmentioning

confidence: 99%